![Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis - The Lancet Psychiatry Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis - The Lancet Psychiatry](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/56937905-3c63-4892-abfc-5436d180697f/gr1_lrg.gif)
Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis - The Lancet Psychiatry
![Cheap antidepressant commonly used to treat obsessive-compulsive disorder significantly decreased the risk of Covid-19 patients becoming hospitalized in a large trial. A 10-day course of the antidepressant fluvoxamine cut hospitalizations by two-thirds Cheap antidepressant commonly used to treat obsessive-compulsive disorder significantly decreased the risk of Covid-19 patients becoming hospitalized in a large trial. A 10-day course of the antidepressant fluvoxamine cut hospitalizations by two-thirds](https://external-preview.redd.it/cW6UxXyHW3XHegMhPKm7I0PKj_SHCRyIVQHj1iKuFHI.jpg?width=640&crop=smart&auto=webp&s=ca64c7576f4aaafde06ea6502521a1cdd930fc07)
Cheap antidepressant commonly used to treat obsessive-compulsive disorder significantly decreased the risk of Covid-19 patients becoming hospitalized in a large trial. A 10-day course of the antidepressant fluvoxamine cut hospitalizations by two-thirds
![Efficacy and safety of transcranial direct current stimulation as an add-on treatment for obsessive-compulsive disorder: a randomized, sham-controlled trial | Neuropsychopharmacology Efficacy and safety of transcranial direct current stimulation as an add-on treatment for obsessive-compulsive disorder: a randomized, sham-controlled trial | Neuropsychopharmacology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41386-020-00928-w/MediaObjects/41386_2020_928_Fig1_HTML.png)
Efficacy and safety of transcranial direct current stimulation as an add-on treatment for obsessive-compulsive disorder: a randomized, sham-controlled trial | Neuropsychopharmacology
![Clinical Uses of Anticonvulsant Drugs Other than for Epilepsy | Journal of Psychosocial Nursing and Mental Health Services Clinical Uses of Anticonvulsant Drugs Other than for Epilepsy | Journal of Psychosocial Nursing and Mental Health Services](https://journals.healio.com/cms/asset/17b25b7e-2dd4-439f-a991-2ca9fcec0345/10.3928_02793695-20200804-79-table1b.jpg)
Clinical Uses of Anticonvulsant Drugs Other than for Epilepsy | Journal of Psychosocial Nursing and Mental Health Services
![Global Obsessive-Compulsive Disorder Drugs Market 2019-2023 | 5% CAGR Projection Over the Next Five Years | Technavio | BioSpace Global Obsessive-Compulsive Disorder Drugs Market 2019-2023 | 5% CAGR Projection Over the Next Five Years | Technavio | BioSpace](https://mms.businesswire.com/media/20190628005248/en/730529/4/Global_Obsessive-Compulsive_Disorder_Drugs_Market_2019-2023.jpg)
Global Obsessive-Compulsive Disorder Drugs Market 2019-2023 | 5% CAGR Projection Over the Next Five Years | Technavio | BioSpace
![PDF) Off-label psychopharmacologic prescribing for children: History supports close clinical monitoring PDF) Off-label psychopharmacologic prescribing for children: History supports close clinical monitoring](https://www.researchgate.net/publication/23259438/figure/tbl2/AS:667221533655049@1536089418440/Common-off-label-uses-of-psychiatric-drugs-in-US-youth_Q320.jpg)
PDF) Off-label psychopharmacologic prescribing for children: History supports close clinical monitoring
![Global Obsessive-Compulsive Disorder Drugs Market 2019-2023 | 5% CAGR Projection Over the Next Five Years | Technavio | Business Wire Global Obsessive-Compulsive Disorder Drugs Market 2019-2023 | 5% CAGR Projection Over the Next Five Years | Technavio | Business Wire](https://mms.businesswire.com/media/20190628005248/en/730529/5/Global_Obsessive-Compulsive_Disorder_Drugs_Market_2019-2023.jpg)